Greenyn Biotechnology Co., Ltd (6846) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Greenyn Biotechnology Co., Ltd TWD 55.58, price TWD 59.10, upside -6.0%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Greenyn Biotechnology Co., Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
53‑month range 52.19 TWD – 101.72 TWD · fair‑value band 36.56 TWD – 79.59 TWD · the 59.10 TWD price screens above the 55.58 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Greenyn Biotechnology Co. in your weekly email
Every Wednesday you see whether Greenyn Biotechnology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink.
Show more
Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, brain health series, body regulation series, throat moistening series, hair care series, clear eye series, colorful lifestyle series, joint health series, nutritional supplement series, energy supplement series, immune modulation series, low burden series, sleep aid series, body curve series, circulation series, man power series, women's intimate health series, and mature woman series. In addition, the company offers customization, ODM, dosage, and application services. Greenyn Biotechnology Co., Ltd was founded in 2012 and is based in Taichung, Taiwan.
Stock analysis
Greenyn Biotechnology Co., Ltd (6846) currently trades at 59.10 TWD, while our model-based Fair Value estimate is 55.58 TWD, implying the stock looks roughly 6.3% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 104.37 TWD per share, and 10 of the 16 models we run sit above the 59.10 TWD price.
Bear case: the Asset-Based group reads lowest at 24.22 TWD, and 6 of the 16 models stay below the price. Evidence for this calculation is medium.
Scenario range: 36.56 TWD (bear) to 79.59 TWD (bull), the price of 59.10 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Greenyn Biotechnology Co., Ltd reported revenue of 915M TWD in FY2025 versus 694M TWD in FY2021, a compound +7.2%/yr. Reported net income was 146M TWD in FY2025, compounding +2.3%/yr from FY2021.
Key figures
Market cap 1.6B TWD (≈ $50.3M) · P/E ratio 15.3 · P/S ratio 2.43 · EPS (TTM) 3.87 TWD · Dividend yield 6.2% · Net margin 15.9% · Return on assets (EBIT) 15.6% · Free cash flow −236M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −6%, 6846 screens richer than that median.
Fair Value models
Bear 36.56 TWDFair Value 55.58 TWDBull 79.59 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (2.84 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.41/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.2%
Dividend (yield on the price)6.2%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 21%
Compare Greenyn Biotechnology Co., Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score41 · Below median
Fair Value upside−6% · Above median
Profitability
Return on assets0% · Above median
Net margin (TTM)16% · Above median
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Dividend yield (TTM)6.2% · Top 25%
Balance sheet
Debt / equity0.88× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Greenyn Biotechnology Co., Ltd (6846) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 55.58 TWD versus a price of 59.10 TWD, about −6% upside (fairly valued).
What is the fair value of 6846?
Our model-based fair value for Greenyn Biotechnology Co., Ltd is 55.58 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 59.10 TWD.
What is the quality score of 6846?
Greenyn Biotechnology Co., Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Greenyn Biotechnology Co., Ltd (6846)?
Our model-based price target is the fair value of 55.58 TWD (as of Sep 24, 2026) from 16 valuation models. Cautious scenario 36.56 TWD, optimistic scenario 79.59 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Greenyn Biotechnology Co., Ltd stock forecast for 2026?
Our models put fair value at 55.58 TWD, about −6% upside versus a price of 59.10 TWD (fairly valued). Cautious scenario 36.56 TWD, optimistic scenario 79.59 TWD. The calculation is refreshed regularly with new filings.
Does Greenyn Biotechnology Co., Ltd pay a dividend?
Greenyn Biotechnology Co., Ltd currently shows a dividend yield of about 6.23% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Greenyn Biotechnology Co., Ltd (6846)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Greenyn Biotechnology Co., Ltd it is 55.58 TWD per share (as of Sep 24, 2026), against a price of 59.10 TWD. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Greenyn Biotechnology Co., Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6846 trades above its calculated fair value: price 59.10 TWD, fair value 55.58 TWD, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6846?
No. The price is what the market pays today (59.10 TWD); the fair value is what the company's own numbers justify (55.58 TWD). For Greenyn Biotechnology Co., Ltd the two are 3.52 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Greenyn Biotechnology Co., Ltd worth?
The market values Greenyn Biotechnology Co., Ltd at about 1.6B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 59.10 TWD; our models calculate a fair value of 55.58 TWD per share.
What do the bullish and bearish scenarios say about 6846?
Our models span a range for Greenyn Biotechnology Co., Ltd: cautious scenario 36.56 TWD, base 55.58 TWD, optimistic 79.59 TWD per share (as of Sep 24, 2026, price 59.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6846?
Greenyn Biotechnology Co., Ltd trades at a price-to-earnings ratio of 15.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 55.58 TWD is built from several models across several years. Other multiples: P/B 0.1.
How solid is the balance sheet of Greenyn Biotechnology Co., Ltd (6846)?
Balance-sheet figures for Greenyn Biotechnology Co., Ltd (as of Sep 24, 2026): debt of 0.88 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 6846 from its 52-week high?
Greenyn Biotechnology Co., Ltd trades at 59.10 TWD, about 19% below its 52-week high of 73.31 TWD and 4% above the low of 57.00 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 55.58 TWD is for.
Which stocks are comparable to Greenyn Biotechnology Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Greenyn Biotechnology Co., Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 59.10 TWD, calculated fair value 55.58 TWD (−6%), Quality Score 41/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6846 calculated?
We run Greenyn Biotechnology Co., Ltd through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 55.58 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Greenyn Biotechnology Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Greenyn Biotechnology Co., Ltd (6846)?
The closing price on Sep 24, 2026 was 59.10 TWD. Our model-based fair value is 55.58 TWD, about −6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Greenyn Biotechnology Co., Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (36.56 TWD to 79.59 TWD) leaves room in how you read the outcome.
Key figures of Greenyn Biotechnology Co., Ltd
How large is the market capitalisation of Greenyn Biotechnology Co., Ltd (6846)?
The market capitalisation of Greenyn Biotechnology Co., Ltd is 1.6B TWD (≈ $50.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Greenyn Biotechnology Co., Ltd (6846)?
The price-to-sales ratio of Greenyn Biotechnology Co., Ltd is 2.43 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Greenyn Biotechnology Co., Ltd (6846)?
Earnings per share at Greenyn Biotechnology Co., Ltd are 3.87 TWD (price ÷ EPS = P/E 15.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Greenyn Biotechnology Co., Ltd (6846)?
The dividend yield of Greenyn Biotechnology Co., Ltd is 6.2% (payout 95.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Greenyn Biotechnology Co., Ltd (6846)?
The net margin of Greenyn Biotechnology Co., Ltd is 15.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Greenyn Biotechnology Co., Ltd (6846)?
On an EBIT basis the return on assets of Greenyn Biotechnology Co., Ltd is 15.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Greenyn Biotechnology Co., Ltd (6846) generate?
The free cash flow of Greenyn Biotechnology Co., Ltd is −236M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Greenyn Biotechnology Co., Ltd (6846) carry?
The net debt of Greenyn Biotechnology Co., Ltd is 69.5M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Greenyn Biotechnology Co., Ltd in the live analysis
One click puts Greenyn Biotechnology Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
